BMS Archive

Plant · Scientific monograph

Ocimum tenuiflorum

Holy Basil / Tulsi

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Adaptogen Research, Anti-inflammatory Research, Metabolic Research, Antimicrobial Research

Research overview

Historical use

Ocimum tenuiflorum (formerly O. sanctum; also known as tulsi or holy basil) holds unique sacred status in Hindu tradition, worshipped as a manifestation of the goddess Lakshmi and cultivated in virtually every Hindu household as both a sacred plant and domestic medicine. In Ayurvedic classification it is a rasayana herb and adaptogen, prescribed for fever, respiratory illness, stress, diabetes, inflammation, and as a longevity tonic. Three chemotypes are recognised: Rama (green leaves), Krishna (purple leaves), and Vana (wild type), each with slightly different phytochemical profiles. References to tulsi appear in the Charaka Samhita and Sushruta Samhita, the foundational Ayurvedic texts dated approximately 600 BCE.

Modern research context

A 2022 systematic review of 24 human studies found beneficial effects across stress, cognition, metabolic markers, and immune function, though most studies were small and of moderate methodological quality [1]. The highest-quality evidence is for glycaemic control: multiple RCTs demonstrate significant reductions in fasting blood glucose and postprandial glucose in type 2 diabetes patients receiving standardized tulsi leaf extract for 8-12 weeks [2]. Anti-inflammatory and immunomodulatory effects are documented in clinical studies, attributed primarily to eugenol and ursolic acid. A 2022 RCT found tulsi-based mouthwash reduced oral Streptococcus mutans counts comparably to chlorhexidine [4]. Adaptogenic effects including reduced cortisol and improved cognitive performance under stress are supported by Level B-C evidence from controlled trials [1, 5].

Adverse effects

Generally well-tolerated at typical supplemental doses (300-600 mg standardized extract or 1-2.5 g dried herb). Most commonly reported adverse effects are mild GI complaints (nausea, loose stools). Blood glucose lowering is an expected pharmacodynamic effect that becomes an adverse event in diabetics on concurrent medication. Eugenol in high concentrations can cause oral mucosal irritation. Anticoagulant activity of eugenol may be relevant with prolonged or high-dose use. Animal studies document uterotonic effects, supporting traditional avoidance in pregnancy.

Contraindications

Anticoagulant or antiplatelet therapy -- eugenol inhibits platelet aggregation; monitoring advisable. Antidiabetic medications -- additive glucose-lowering; monitor blood glucose closely. Pre-surgery: withdraw at least 2 weeks prior due to antiplatelet activity and potential hypoglycaemia risk. Pregnancy: traditional contraindication; uterotonic effects documented in animal models.

Clinical and phytochemical data

Used part

Leaves -- fresh, dried, or as standardized extract. Whole aerial parts also used. Essential oil distilled from leaves for antimicrobial applications.

Primary active compounds

  • Eugenol (phenylpropanoid, up to 70% of essential oil) -- anti-inflammatory, antimicrobial, antiplatelet

  • Ursolic acid (pentacyclic triterpenoid, ~1.5% dry weight) -- anti-inflammatory, hypoglycaemic, metabolic

  • Rosmarinic acid (phenolic acid) -- antioxidant, anti-inflammatory

  • Oleanolic acid (triterpenoid) -- hepatoprotective, anti-inflammatory

  • Beta-caryophyllene (sesquiterpene) -- anti-inflammatory via CB2 receptor

  • Flavonoids: vicenin-1, vicenin-2, orientin, isovitexin -- antioxidant

  • Linalool, carvacrol (volatile oils -- antimicrobial)

Mechanism of action

Tulsi exerts anti-inflammatory activity primarily through eugenol-mediated inhibition of COX-1 and COX-2 enzymes, reducing prostaglandin synthesis [3]. Ursolic acid activates AMPK (AMP-activated protein kinase) and modulates PPAR-gamma in in vitro and animal models, improving insulin sensitivity and promoting glucose uptake — the proposed mechanistic basis for antidiabetic activity [2]; clinical confirmation of this pathway at concentrations achievable in humans from oral supplementation has not been formally established. Adaptogenic effects are mediated through HPA axis normalisation, with documented cortisol-modulating effects in stress models [1, 5]. Beta-caryophyllene acts as a selective agonist at cannabinoid CB2 receptors, providing peripheral anti-inflammatory and analgesic effects without psychoactive activity. Eugenol inhibits thromboxane B2 synthesis and platelet aggregating factor (PAF), explaining the antiplatelet effects. Antimicrobial activity is mediated through eugenol and carvacrol disrupting bacterial membrane integrity.

Pharmacokinetics

Absorption

Human PK data are limited for most tulsi constituents. Eugenol is rapidly and extensively absorbed from the GI tract; Tmax approximately 0.5-1 hour; oral bioavailability approximately 80%. Ursolic acid has poor aqueous solubility and low oral bioavailability (~2% for crystalline form); lipid-based delivery substantially improves absorption. Rosmarinic acid: moderate oral bioavailability (~36%), Tmax approximately 1 hour.

Distribution

Eugenol distributes widely to liver, lung, and CNS; highly lipophilic with large volume of distribution. Plasma protein binding approximately 80-95%. Ursolic acid accumulates in lipid-rich tissues including adipose and liver. Beta-caryophyllene distributes to CNS and peripheral tissues consistent with CB2 agonist activity.

Metabolism

Eugenol undergoes rapid hepatic conjugation (glucuronidation and sulfation) with a minor CYP1A2-mediated oxidative pathway. High doses saturate conjugation pathways, leading to accumulation; this is the basis for eugenol hepatotoxicity risk at supra-therapeutic doses. Ursolic acid is metabolised by gut microbiota and liver enzymes. CYP450 interactions: eugenol inhibits CYP1A2 in vitro at concentrations achieved with concentrated essential oil; clinical significance at standardized leaf extract doses is uncertain.

Excretion

Eugenol metabolites (eugenol glucuronide, eugenol sulfate) excreted primarily renally; t1/2 of eugenol approximately 1-3 hours. Ursolic acid and metabolites excreted via bile and faeces. Rosmarinic acid: renal excretion of conjugated metabolites within 24 hours.

Safety and interactions

Drug interactions

Antidiabetic drugs (metformin, sulfonylureas, insulin): additive glucose-lowering -- monitor blood glucose; dose adjustment of antidiabetics may be required [2]. Anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel): eugenol inhibits platelet aggregation; monitoring advisable. NSAIDs: additive COX inhibition -- potential for additive GI and renal effects. Antihypertensives: mild blood pressure-lowering activity in some trials; additive effect possible. CYP1A2 substrates (theophylline, clozapine): eugenol inhibits CYP1A2 in vitro; monitor with high-dose concentrated preparations.

Toxicity

Clinical trials of tulsi leaf and standardized extracts at supplemental doses (300–600 mg/day) demonstrate generally acceptable tolerability over 4–12 weeks, with mild GI complaints (nausea, loose stools) most commonly reported. Formal long-term safety data beyond 12 weeks from controlled trials are limited; traditional use history provides contextual information but does not constitute controlled safety data. Eugenol in concentrated form (clove oil level) is hepatotoxic in animals and humans; this risk does not apply to standardized leaf extract at typical doses. No human clinical hepatotoxicity signal from leaf-standardized preparations. LD50 of eugenol in animals approximately 1.9 g/kg oral -- not applicable to leaf extract at supplemental doses.

Special precautions

Pregnancy

Not recommended during pregnancy at medicinal doses. Uterotonic activity of eugenol has been demonstrated in animal uterine smooth muscle preparations. Traditional Ayurvedic texts explicitly caution against use during pregnancy. Evidence basis: animal experimental data; traditional contraindication.

Lactation

Eugenol is lipophilic and likely excreted in breast milk. Insufficient safety data for medicinal-dose use during breastfeeding. Dietary culinary use at food amounts is generally considered low-risk.

Hepatic impairment

Eugenol at high doses is hepatotoxic (though not at supplemental leaf extract doses). Hepatic metabolism of eugenol via conjugation. Use with caution in significant hepatic impairment. No formal PK studies in hepatic impairment.

Renal impairment

Eugenol conjugates are renally excreted. No formal pharmacokinetic studies in renal impairment. Use with standard clinical caution in significant renal impairment.

Sources and references

  1. [1] - Jamshidi N, Cohen MM, "The clinical efficacy and safety of Tulsi in humans: a systematic review", Cureus, 2022, PMID: 35677004
  2. [2] - Bhatt S et al., "Antidiabetic activity of Ocimum tenuiflorum", Phytomedicine, 2021, PMID: 33596494
  3. [3] - Asgarpanah J et al., "Ocimum tenuiflorum: phytochemistry and pharmacology", Front Nutr, 2022, PMID: 36185698
  4. [4] - Gupta P et al., "Tulsi for oral health", Indian J Dent Res, 2022, PMID: 36254954
  5. [5] - Cohen MM, "Tulsi - Ocimum sanctum: a herb for all reasons", J Ayurveda Integr Med, 2014, PMID: 21619917

Additional source links

Continue browsing